EUVIMEDEUVIMED entdecken
Crossref

Whole-Genome Sequencing Analysis of Male Breast Cancer Unveils Novel Structural Events and Potential Therapeutic Targets

Majd Al Assaad, Olivier Michaud, Alissa Semaan, Michael Sigouros, Marvel Tranquille, Andy Phan, Max F Levine, Gunes Gundem, Juan S Medina-Martínez, Elli Papaemmanuil, Jyothi Manohar, David Wilkes und 4 weitere

Modern Pathology · 2024

DOI: 10.1016/j.modpat.2024.100452 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2024. Verfasst von Majd Al Assaad und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York; Englander Institute for Precision Medicine, Weill Cornel…. Hauptthemen laut MEDLINE: Breast Neoplasms, Male, Breast Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 69 Literaturangaben. Gefördert von: Department of Pathology, Northwestern University, Weill Cornell Medicine - Department of Pathology and Laboratory Medicine, Weill Cornell Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The molecular characterization of male breast cancer (MaBC) has received limited attention in research, mostly because of its low incidence rate, accounting for only 0.5% to 1% of all reported cases of breast cancer each year. Managing MaBC presents significant challenges, with most treatment protocols being adapted from those developed for female breast cancer. Utilizing whole-genome sequencing (WGS) and state-of-the-art analyses, the genomic features of 10 MaBC cases (n = 10) were delineated and correlated with clinical and histopathologic characteristics. Using fluorescence in situ hybridization, an additional cohort of 18 patients was interrogated to supplement WGS findings. The genomic landscape of MaBC uncovered significant genetic alterations that could influence diagnosis and treatment. We found common somatic mutations in key driver genes, such as FAT1, GATA3, SMARCA4, and ARID2. Our study also mapped out structural variants that impact cancer-associated genes, such as ARID1A, ESR1, GATA3, NTRK1, and NF1. Using a WGS-based classifier, homologous recombination deficiency (HRD) was identified in 2 cases, both presenting with deleterious variants in BRCA2. Noteworthy was the observation of FGFR1 amplification in 21% of cases. Altogether, we identified at least 1 potential therapeutic target in 8 of the 10 cases, including high tumor mutational burden, FGFR1 amplification, and HRD. Our study is the first WGS characterization of MaBC, which uncovered potentially relevant variants, including structural events in cancer genes, HRD signatures, and germline pathogenic mutations. Our results demonstrate unique genetic markers and potential treatment targets in MaBC, thereby underlining the necessity of tailoring treatment strategies for this understudied patient population. These WGS-based findings add to the growing knowledge of MaBC genomics and highlight the need to expand research on this type of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast Neoplasms, MaleBreast NeoplasmsHumansMaleFemaleIn Situ Hybridization, FluorescenceMutationOncogenesGerm-Line MutationDNA HelicasesNuclear ProteinsTranscription Factors

Stichwörter der Autor:innen

breast cancergenomicshomologous recombination deficiencystructural variantswhole-genome sequencing

Substanzen

SMARCA4 protein, humanDNA HelicasesNuclear ProteinsTranscription Factors

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York.
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York; Département de Pathologie, Université Laval, Quebec City, Quebec, Canada.
  • Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York.
  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York.
  • Isabl, Inc, New York, New York.
  • Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, New York; Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York; Institute for Computational Biomedicine, Weill…

Förderung

  • Department of Pathology, Northwestern University
  • Weill Cornell Medicine - Department of Pathology and Laboratory Medicine
  • Weill Cornell Medicine

Zitieren

APA

Al Assaad, M., Michaud, O., Semaan, A., Sigouros, M., Tranquille, M., Phan, A., Levine, M. F., Gundem, G., Medina-Martínez, J. S., Papaemmanuil, E., Manohar, J., Wilkes, D., Sboner, A., Hoda, S. A. F., Elemento, O., & Mosquera, J. M. (2024). Whole-Genome Sequencing Analysis of Male Breast Cancer Unveils Novel Structural Events and Potential Therapeutic Targets. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100452

Vancouver

Al Assaad M, Michaud O, Semaan A, Sigouros M, Tranquille M, Phan A, et al. Whole-Genome Sequencing Analysis of Male Breast Cancer Unveils Novel Structural Events and Potential Therapeutic Targets. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100452

BibTeX
@article{AlAssaad2024,
  author = {Al Assaad, Majd and Michaud, Olivier and Semaan, Alissa and Sigouros, Michael and Tranquille, Marvel and Phan, Andy and Levine, Max F and Gundem, Gunes and Medina-Martínez, Juan S and Papaemmanuil, Elli and Manohar, Jyothi and Wilkes, David and Sboner, Andrea and Hoda, Syed A F and Elemento, Olivier and Mosquera, Juan Miguel},
  title = {Whole-Genome Sequencing Analysis of Male Breast Cancer Unveils Novel Structural Events and Potential Therapeutic Targets},
  journal = {Modern Pathology},
  year = {2024},
  doi = {10.1016/j.modpat.2024.100452}
}
Kostenlos starten →